1. Home
  2. Browse
  3. National Institutes of Health
  4. PAR-25-265

PAR-25-265National Institutes of HealthR01

Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)

Deadline
Award ceiling
Not stated
Awards
Not stated
Posted
Dec 2, 2024

Official announcement on the NIH Guide · opens the funder's page. Always confirm dates there.

Or read the full text and all 3 review criteria here, free with an account. Create free account

Summary

This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future.Having an accurate…

Related NIH announcements6

Companion announcements with the same title first, then other open R01 announcements on related subjects with at least two weeks to go.

Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)

PAR-25-266National Institutes of Health3 review criteria on file

$200k

NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)

PAR-25-271National Institutes of Health3 review criteria on file

—

Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)

PAR-25-336National Institutes of Health4 review criteria on file

—

Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)

PAR-25-268National Institutes of Health3 review criteria on file

—

NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)

PAR-25-267National Institutes of Health3 review criteria on file

$350k

Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)

RFA-DA-26-034National Institutes of Health3 review criteria on fileagency framework

$300k

The full announcement, free with an account

  • The full announcement text, not just the first two sentences
  • All 3 review criteria reviewers score this against, extracted from this announcement

On Plus, $39 a month

  • The eligibility check against your profile: career stage, institution type, and the windows that close before the deadline does
  • Funded precedents: what similar NIH projects received, from the award records in NIH RePORTER
  • A Reviewer Scorecard of your draft against these criteria
Create free accountSign in

No card required. Browsing is free.

More from National Institutes of Health

Open now with at least two weeks to apply, soonest deadline first.

NIDCR Drug, Biologic, Device and/or Procedure Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)

PAR-25-057National Institutes of Health6 review criteria on file

—

Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed)

RFA-DK-27-108National Institutes of Health3 review criteria on fileagency framework

$500k

Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)

RFA-DK-27-139National Institutes of Health

—

Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)

RFA-DK-27-112National Institutes of Health

—

Everything open from National Institutes of Health

Source record: https://grants.nih.gov/grants/guide/pa-files/PAR-25-265.htmlVia the NIH Guide. Last checked against the source . Always confirm dates with the funder.